Neither analysis of PD-L1 nor of tumor mutational burden constitutes perfect biomarkers for the response to immunotherapy, and positive results of immune checkpoint inhibitors may be seen in some marker-negative patients. The gene discussed is CD274; the disease is neoplasm.